特发性肺纤维化肺虚络瘀证病证结合生物标志物

Idiopathic pulmonary fibrosis (lung deficiency and collateral obstruction syndrome) combined with disease and syndrome biomarkers

特发性肺纤维化(IPF)是一种慢性、进展性疾病,目前缺乏安全、有效的治疗手段,而生物标志物的发现可以协助判断IPF的结局,预测疾病的转归,为诊断和治疗IPF提供了新的思路。文章以IPF肺虚络瘀证为切入点,从分子生物水平对证候进行研究,基于病证结合生物组学的相关研究方法,构建分子生物学调控网络,寻找IPF肺虚络瘀证相关的生物标志物,体现构建病证结合(IPF肺虚络瘀证)生物标志物的价值,从分子水平揭示IPF肺虚络瘀证发病病机、生物学内涵以及病机格局转变。

Idiopathic pulmonary fibrosis(IPF)is a chronic,progressive disease that currently lacks safe and effective treatments,and the discovery of biomarkers can help determine the outcome of IPF and predict the outcome of the disease for diagnosis and treatment.IPF provides a new idea.This article takes idiopathic pulmonary fibrosis and lung deficiency syndrome as the entry point,studies the syndrome from the molecular biological level,and constructs molecular biology based on the relevant research methods of disease syndrome and bionomics.Molecular biological regulation network was constructed to search for biomarkers related to IPF syndrome of lung deficiency and collaterals stasis,which reflected the value of constructing biomarkers combining disease and syndrome(IPF syndrome of lung deficiency and collaterals stasis),and revealed the pathogenesis biological connotation and pathogenesis pattern transformation of IPF syndrome of lung deficiency and collaterals stasis from the molecular level.